<DOC>
	<DOC>NCT00044512</DOC>
	<brief_summary>Evaluate anti-cancer activity (e.g. proportion of patients with confirmed complete response or partial response) in patients with advanced, inoperable biopsy-proven hepatocellular carcinoma.</brief_summary>
	<brief_title>A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma</brief_title>
	<detailed_description>In addition to the key secondary outcome parameters the following exploratory parameters were evaluated in subpopulations: - Pharmacokinetics (PK) profile of Sorafenib - Plasma and tissue tumor biomarkers</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically or cytologically confirmed primary hepatocellular carcinoma (HCC) Inoperable disease (T2T4, any N, M0 or M1) or refused surgery Measurable disease At least 1 bidimensionally measurable lesion of at least 2 cm by computed tomography (CT) scan or magnetic resonance imaging (MRI) Presence of at least 1 of the following: Alphafetoprotein greater than the upper limit of normal (ULN) Hepatitis C antibody positive Hepatitis B surface antigen positive Child's Pugh class A or B Candidate for systemic therapy Fibrolamellar disease mixed histology Metastatic brain or meningeal tumors</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Liver Cancer</keyword>
	<keyword>Hepatocellular carcinoma (HCC)</keyword>
</DOC>